We are live on ! Find out more
MNTA

Momenta Pharmaceuticals, Inc.
MNTA

Delisted

MNTA was delisted on the 30th of September, 2020.

Back to rankings

1 hedge funds and large institutions have $116K invested in Momenta Pharmaceuticals, Inc. in 2021 Q3 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
1
Holders Change
+1
Holders Change %
–
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NICM
Neo Ivy Capital Management
New York
+$116K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
NICM
1
Neo Ivy Capital Management
New York
$116K +$116K +3,497 New

MNTA Hedge Fund Activity: Q3 2021 in Review

1 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q3 2021, worth a combined $116K.

Buyers outnumbered sellers: 1 fund opened new MNTA positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Neo Ivy Capital Management, opening a new position worth an estimated $116K.

  • 1 institutional investor held Momenta Pharmaceuticals, Inc. (MNTA) as of Q3 2021, up from 0 in Q2 2021.
  • Funds reported $116K of Momenta Pharmaceuticals, Inc. stock for Q3 2021.
  • 1 fund opened new Momenta Pharmaceuticals, Inc. positions in Q3 2021 and 0 closed out, a net change of +1 holder.
  • The largest Momenta Pharmaceuticals, Inc. buyer in Q3 2021 was Neo Ivy Capital Management, an estimated $116K added.

Based on aggregated 13F filings for Q3 2021.